Clavis Pharma
- Country
- 🇳🇴Norway
- Ownership
- Private
- Established
- 2001-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
18
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Elacytarabine Mass Balance Study in Healthy Volunteers
- Conditions
- Not Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy Subjects
- Interventions
- Drug: [14C]-Elacytarabine
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2013-08-28
- Lead Sponsor
- Clavis Pharma
- Target Recruit Count
- 6
- Registration Number
- NCT01783964
- Locations
- 🇬🇧
Quotient Clinical, Ruddington, Nottngham, United Kingdom
The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)
- Conditions
- Relapsed/Refractory AML
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2013-09-23
- Lead Sponsor
- Clavis Pharma
- Target Recruit Count
- 43
- Registration Number
- NCT01258816
- Locations
- 🇪🇸
ICO - Hospital Duran i Reynals, Barcelona, Catalunya, Spain
🇪🇸Hospital General de la Vall d' Hebron, Barcelona, Spain
🇪🇸Hospital San Pedro Alcantara, Cáceres, Spain
Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Drug: Investigator's Choice
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2013-09-27
- Lead Sponsor
- Clavis Pharma
- Target Recruit Count
- 381
- Registration Number
- NCT01147939
- Locations
- 🇺🇸
Scripps Cancer Center Clinical Research, La Jolla, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸UCLA School of Medicine, Division of Hematology/Oncology, Los Angeles, California, United States
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
- First Posted Date
- 2009-12-18
- Last Posted Date
- 2013-09-27
- Lead Sponsor
- Clavis Pharma
- Target Recruit Count
- 51
- Registration Number
- NCT01035502
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇫🇷CHU Lyon, Hospital Edouard Herriot, Lyon, France
🇫🇷Institut Paoli-Calmettes, Marseille, France
A Study of CP-4126 in Patients With Advanced Pancreatic Cancer
- Conditions
- Advanced Adenocarcinoma of Pancreas
- Interventions
- Drug: IV CP-4126
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2012-02-10
- Lead Sponsor
- Clavis Pharma
- Target Recruit Count
- 21
- Registration Number
- NCT00913198
- Locations
- 🇧🇪
Clinique d'Oncologie Médicale, Institut Jules Bordet, Brussels, Belgium
🇳🇴Oslo University Hospital, The Norwegian Radium Hospital,, Oslo, Norway
🇳🇴Oslo University Hospital, Ullevål, Oslo, Norway
- Prev
- 1
- 2
- 3
- Next